The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of CareLocker to enhance Bleepa technology

9 Sep 2021 07:00

RNS Number : 1876L
Feedback PLC
09 September 2021
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

Feedback plc

 

Feedback announces launch of CareLocker to enhance its Bleepa technology

 

· Revolutionary GDPR compliant patient-centric cloud architecture to underly the Bleepa platform

· Increases the opportunities for Bleepa adoption across multiple care settings

· Proprietary technology enables an easy route to creation and mobilisation of individual healthcare records

· The perfect infrastructure to support roll-out of regional care delivery programmes such as the Community Diagnostic Hub initiative

 

London, 09 September 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that it is launching a new Bleepa product - CareLocker.

 

CareLocker is a new proprietary and patient-centric cloud architecture that supports Bleepa's functionality whilst simultaneously creating patient specific records of care episodes. CareLocker will enable Bleepa to deliver care across provider settings in a secure and scalable way.

 

Bleepa provides practitioners with mobile access to patient data, including medical images, allowing secure communication and on-the-go decision making. As a clinical tool Bleepa integrates with multiple hospital systems and centralises relevant clinical data around specific patient episodes, from which clinical teams can accelerate decision making capabilities through the platform. This data includes lab results, structured reports, ECGs and most importantly medical images, which are uniquely displayed through Bleepa's regulated DICOM viewer. CareLocker provides a patient-centric way of storing data and because the patient record is de-centralised, they can be accessed by any care setting through open Application Programming Interfaces (APIs) such as FHIR.

 

CareLocker provides patient-centric cloud data stores: containers that store medical data at an individual patient level. With this proprietary architecture, patient data can be secured at the individual level, with access control even to subsets of a patient's data. CareLocker offers opportunities for improved storage optimisation making it more cost effective than traditional data storage architectures. Most importantly, CareLockers can be built on a patient-by-patient basis, allowing organisations to transition to a cloud architecture as patients enter care pathways rather than having to undertake the mass data migrations usually associated with cloud transitions.

 

Where Bleepa is installed in multiple regional provider settings, the migration of data into a patient specific record can happen at a regional level, breaking down provider siloes. One topical area of application is in facilitating the £10bn Community Diagnostic Hub (CDH) initiative launched by NHS England to help address the elective care backlog by bringing diagnostic services out of hospital settings and closer to patients.[1] CDHs will typically complete a suite of diagnostic tests, the results of which must all be made available to the clinical teams, both in the primary and secondary care setting, creating a patient pathway that bridges multiple care settings. This end-to-end patient-specific pathway requires a digital infrastructure designed to both connect clinical teams and manage the associated data flow. Bleepa and CareLocker in combination provide this, with Bleepa as an application and user interface and CareLocker as the underlying data architecture.

 

Dr Tom Oakley, CEO of Feedback, said: "CareLocker is the latest development in the Bleepa story and has the potential to be a significant catalyst to multiple commercial opportunities. We have been working on this concept for many months in order to position Bleepa for multi-site adoption and to meet the emerging needs of the CDH initiative to address the elective care backlog. Currently patient data is siloed within disparate hospital systems and within individual clinical settings, this makes delivering regional care extremely difficult. In some cases it can take hours to transfer imaging between two hospitals and this ultimately effects patient care. CareLocker is a solution that can transform care delivery at an individual hospital, regional or even national level. Patient-centric cloud storage is the future of medical data and a natural result of patient centred care. We believe Carelocker provides the platform our customers need and is right at the cutting edge of communication technology. With this platform in place we will be accelerating the opportunities for adoption across multiple settings."

 

Further information on CareLocker can be found on the Company's website www.fbkmed.com

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

 

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

 

 

[1] https://uk.eu-supply.com/ctm/Supplier/PublicTenders/ViewNotice/26333

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLUWUWRASUKRAR
Date   Source Headline
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.